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Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease associated with motor neuron degeneration,
muscle atrophy and paralysis. To date, multiple panels of biomarkers have been described in ALS patients and murine
models. Nevertheless, none of them has sufficient specificity and thus the molecular signature for ALS prognosis and
progression remains to be elucidated. Here we overcome this limitation through a longitudinal study, analyzing serum
levels of circulating miRNAs, stable molecules that are recently used as promising biomarkers for many types of human
disorders, in ALS patients during the progression of the pathology. We performed next-generation sequencing (NGS)
analysis and absolute RT quantification of serum samples of ALS patients and healthy controls. The expression levels of
five selected miRNAs were quantitatively analyzed during disease progression in each patient and we demonstrated
that high levels of miR-206, miR-133a and miR-151a-5p can predict a slower clinical decline of patient functionality. In
particular, we found that miR-206 and miR-151a-5p serum levels were significantly up-regulated at the mild stage of
ALS pathology, to decrease in the following moderate and severe stages, whereas the expression levels of miR-133a
and miR-199a-5p remained low throughout the course of the disease, showing a diagnostic significance in moderate
and severe stages for miR-133a and in mild and terminal ones for miR-199a-5p. Moreover, we found that miR-423–3p
and 151a-5p were significantly downregulated respectively in mild and terminal stages of the disease. These data
suggest that these miRNAs represent potential prognostic markers for ALS disease.
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurode-
generative disease associated with motor neurons degen-
eration, muscle atrophy and paralysis1. In addition, energy
balance is severely compromised in ALS patients, owing
to higher consumption than intake with increased resting
energy use, along with abnormal lipid metabolism2–6.
Diagnosis of ALS relies on clinical, electrophysiological
or neuropathological examination and is based on the
exclusion of alternative related pathologies7,8.
ALS can proceed with different aggressiveness and
velocity; nevertheless, the characterization of specific
molecular mechanisms and potential molecular bio-
markers of the progression of the disease remain to be
fully elucidated. Thus, the definition of biomarkers of ALS
that can be included in the diagnosis and prognosis of the
disease, will help to better restrict the phenotypes of ALS,
and where appropriate, to enroll the patients with a spe-
cific molecular signature in clinical trials.
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MicroRNAs (miRNAs) are evolutionary conserved non
coding RNA molecules with post-transcriptional reg-
ulatory role and are frequently dysregulated in human
disease9–11. Moreover, tissue-specific miRNAs, normally
restricted in the tissue of expression, can be released in
the blood, under pathological conditions. Thus, there is an
increase interest to define their role in the pathogenesis of
several degenerative diseases, as minimally invasive and
low- cost disease biomarkers12.
Recent studies report the identification of potential
circulating miRNAs, namely miR-4649–5p, miR-424,
miR-133a, and miR-206, as putative serum biomarkers for
ALS diagnosis13–15.
To add further insights into the potential molecular
biomarkers of ALS and to define potential miRNA sig-
nature for ALS progression, we performed next-
generation sequencing (NGS) using serum from both
ALS patients and healthy controls and identified a general
downregulation of miRNAs expression in ALS patients
respect to controls.
Here we analyzed circulating levels of five specific
miRNAs (miR-206, miR-133a, miR-199a-5p, miR-151a-
5p, and miR-423–3p) in sera, periodically collected every
3 months, from ALS patients. Through a longitudinal
analysis, we demonstrated that early phases of ALS
pathology are characterized by low levels of miR-199a-5p,
miR-133a and mir-423–3p and by high levels of miR-
151a-5p and miR-206, which also predicted a slower
clinical decline of patient functionality, suggesting that
these miRNAs can represent potential prognostic markers
for ALS disease and valid biomarkers to stratify the
severity of disease progression.
Results
Differential expression of serum miRNAs in ALS patients
compared to healthy controls
To gain insight into the circulating miRNAs expres-
sion in ALS, NGS was performed, using Small RNA
sequencing technology (Illumina), on RNA isolated
from serum of 13 ALS patients along with 6 matched
healthy controls. The cohort analyzed was constituted
of 10 sporadic (sALS, mean age 58.1 ± 8.4) and 3
familiar (fALS, mean age 54 ± 5.7) ALS patients com-
prising 7 males and 6 females; among them 4 were
characterized by bulbar onset, 8 by spinal onset, while
one by both spinal/bulbar onset (Supplementary Fig.
S1a). The abundance of microRNAs analyzed was nor-
malized towards a synthetic endogenous control (cel-
lin-4) that was added to the serum samples before the
RNA extraction. The sequencing revealed a clear clus-
tering of ALS samples on one side, and of healthy
controls on the other side (Supplementary Fig. S1b).
Interestingly, we identified 585 miRNAs expressed in all
the serum samples analyzed and we observed a
significant downregulation of 152 miRNAs of them,
with no miRNAs significantly upregulated (Fig. 1a).
In order to identify suitable biomarkers candidates, we
selected, from NGS data, three relevant miRNAs (miR-
151a-5p, miR-199a-5p, miR-423–3p) that resulted sig-
nificantly downregulated in ALS patients compared to
healthy controls (Fig. 1b).
The decreased expression levels of the miRNAs, iden-
tified by NGS, were validated by qPCR in sera derived
from different cohort of ALS patients and healthy control
subjects, namely 9 males and 10 females sALS patients
(mean age 56.6 ± 10.9), 2 males and 2 females fALS
patients (mean age 56 ± 9.9) and 11 matched healthy
controls (6 males and 5 females, mean age 50.0 ± 10.1)
(Supplementary Fig. S1,c).
The three miRNAs (miR-151a-5p, miR-199a-5p, miR-
423–3p), were robustly and significantly downregulated in
both sporadic and familiar ALS cases compared to healthy
controls (Fig. 1c).
MiRNAs expression levels are differentially modulated in
ALS patients during disease progression
To assess the role of selected miRNAs as prognostic
biomarkers, their expression levels were quantified in
serum samples from healthy controls (age 55.0 ± 11.2) and
patients (age 69.5 ± 9.6) that were collected every
3 months for a maximum of 30 months of follow-up. We
analyzed both male and female with diagnosed spinal
onset ALS disease and by ALS Functional Rating Score
(ALS-FRS) (Table 1).
Clinical course of ALS pathology is highly variable and
the duration of the disease ranges from months to more
than two decades after onset16. In order to disclose a
possible difference in disease progression of patients
enrolled in our study, we evaluated the decline in the
clinical rate of patients enrolled in the study.
We initially associated the ALS-FR score, collected
during the whole study, to an exponential model
(Fig. 2a)17 to obtain a rate decline value (K value) for each
patient; successively, we categorized the ALS-FR score
into two groups using a k-means cluster categorization of
the K value decline parameters18. Thus, the patient’s
cohort was divided into two significantly different sub-
cohorts (inset in Fig. 2): 11 patients with lower rate
decline—the slow progressive patients (K value 0,02024 ±
0,01392)—and 6 with higher rate decline—the fast-
progressive patients (K value 0,1167 ± 0,02923); the cate-
gorization was further corroborated by survival curves
analysis (Fig. 2b).
To understand whether miRNAs modulation was rela-
ted to stage disease, we analyzed the expression levels of
two myo-miR (miR-206 and miR-133a) together with the
three of the newly identified deregulated miRNAs (miR-
199a-5p, miR-151a-5p, and miR-423–3p) in the cohort of
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Fig. 1 NGS analysis of miRNAs expression in healthy and ALS patients. a MA plot and b expression heatmap of miRNAs expression in healthy
and ALS patient sera showing selected downregulated serum miRNAs from sALS and fALS patients compared with healthy controls (CNT). Blue
represents downregulation and yellow represents upregulation. Gender, age, and samples ID are indicated. In the scatter plot, log2 fold change of
miRNA expression values between healthy and ALS patient sera are plotted against the mean of DESeq2 miRNA normalized read counts. Negative
fold changes reflect depletion in ALS patient sera. Dots are colored red if the adjusted p-value for the differential expression test is less than 0.1.
c qPCR validation by relative quantification of miR-151a-5p, miR-199a-5p and miR-423-3p in serum samples of 19 sALS and 4 fALS patients with
respect to 11 healthy controls. All data were normalized for a spiked miRNA (cel-lin-4) and expressed as fold change with respect to a healthy control
set to a value of 1.
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patients stratified for disease stage. Indeed, we divided the
patient cohort in 4 stages classified as mild (I), moderate
(II), severe (III), and terminal (IV) (Table 1) on the basis of
health state of patient (HSS) estimated by ability to speak
and to perform physical functions in carrying out activ-
ities of daily living19,20.
As shown in Fig. 3a, we observed that circulating levels
of miR-206 were significantly increased in the moderate
stage of the disease (healthy control 249.9 ± 62.7 copies,
moderate 1686 ± 691.5 copies) and decreased of about
74.51% (527.3 ± 117.0 copies) and 90.96 % (186.9 ± 55.59
copies), respectively in the severe and terminal stage if
compared to the mild one (Fig. 3a).
At the same time, miR-133a and miR-199a-5p levels
were down-modulated all along disease progression. In
particular, miR-133a significantly decreased in moderate,
severe, and terminal stages of the disease (respectively
−70.0%, −78.8%, −76.4%), whereas miR-199a-5p
remained significantly lower in both the first and in
terminal stage of the pathology (miR-133a control
2033 ± 579.9 copies, moderate 611.7 ± 102.0 copies,
severe 430.1 ± 101.6 copies, terminal 479.6 ± 179.7 miR-
199a-5p control 11944 ± 3376 mild 3646 ± 516.9 term-
inal 3863 ± 882.0 copies) (Fig. 3b, c).
Of note, miR-199a-5p and miR-423–3p were the only
two miRNAs that resulted down-modulated at the first
stage if compared to healthy control individuals (miR-
423–3p control 22525 ± 5820 copies, mild 7630 ± 917.2
copies) (Fig. 3c, d). Interestingly miR-151a-5p remained at
higher levels compared to those of healthy control indi-
viduals during disease progression with just a significant
drop of its levels at the terminal stage of the pathology
similarly to all the analyzed miRNAs (miR-151a-5p con-
trol 10943 ± 2435 copies, moderate 25703 ± 4856 copies,
severe 26917 ± 4302 copies, terminal 8995 ± 1771copies)
(Fig. 3e).
All together these data demonstrate that miR-206, miR-
133a, miR-151a-5p, miR-199a-5p and miR-423–3p are
modulated during disease progression and they can be
considered good biomarkers of most ALS disease stages.
MiRNAs expression levels are differentially modulated in
slow and fast disease progressing patients
To define potential different distribution of microRNAs
in patients with different progression of the disease, we
plotted the copies number of miR-206, miR-133a, miR-
151a-5p for each patient divided in fast and slow pro-
gressive groups, from enrollment to the clinical end point
(Fig. 4a, c, e).
Interestingly, most of the slow progressive patients
showed higher level of the miRNAs analyzed at the time
of enrollment, while fast progressive disease patients
showed lower copies number of miRNAs during disease
progression. (Fig. 4a, c, e).
In particular, the linear regression analysis of miRNAs
copies number during disease progression highlighted a
significant difference between the intercepts of fast and
slow progressive linear regression curves for miR-206,
miR-133a, miR-151a-5p (Fig. 4a, c, e), whereas linear
regression analysis of miR199a-5p and miR423–3p
revealed no statistical significance for these miRNAs
(Supplementary Fig. S2a and S2b).
Roc analysis of the miRNAs levels, performed at time of
enrollment, revealed that the copies number of miRNAs
can discriminate fast and slow progressing patients at
early stage of the disease (best cut-off miR-206 ≤ 145.1
copies/200 μl serum, miR-133a ≤ 108.2 copies/200 μl
serum, miR-151a-5p ≤ 11183 copies/200 μl serum)
(Fig. 4b, d, f).
Overall, these data demonstrate that higher level of
miR-206, miR-133a, and miR-151a-5p can predict a slow
progression of the disease and a better prognosis.
Creatin phosphokinase, albumin and alkaline phosphatase
levels are differentially modulated in slow and fast
progressive patients
ALS patients show distinct serological profiles and,
therefore, numerous hematological factors are usually
analyzed in relation to severity of clinical status of the
ALS patients20. Here we investigated the serum levels of
creatin phosphokinase (CPK), albumin and alkaline
phosphatase (ALP), which are considered good markers of
individuals health as they reflect the state of muscle mass,
the inflammatory and nutritional status and liver func-
tionality of the individuals enrolled in the study18.
We analyzed serum level of CPK, Albumin and ALP
during disease progression in both slow and fast pro-
gressing patients. As reported in Fig. 5a, the CPK levels
decrease in both fast and slow progressing patients in line
with previous evidence21,22, and the linear regression
Table 1 Demographic and clinical data of patients and
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analysis highlighted a significant difference in the slope of
the CPK linear curve. In particular, the slope or rate
decline of the slow progressing patients resulted sig-
nificantly smaller compared with the fast progressing ones
(p ≤ 0.001).
In contrast, we did not observe any significant differ-
ence in the slope of the linear regression curve of Albu-
min and ALP. As shown in Fig. 5 the levels of Albumin
and ALP remained flat or slightly increased in fast pro-
gressive patients if compared to slow one (Fig. 5b, c).
All together these data suggest that CPK hematic
levels can be useful for clinical evaluation of ALS
patients and represent a good support for the prognostic
significance of miR-206, miR-133a and miR-151a-5p in
ALS disease.
Discussion
ALS is a multifactorial and multisystemic pathology in
which severe alterations in several tissues and cell com-
partments, such as motor neurons, glia, and muscle, act
synergistically to affect disease onset and progression1.
Due to the complexity of the pathogenetic mechanism,
the progression of the disease is highly variable proceed-
ing in affected individuals with different aggressiveness
and velocity23. The reason for the great variability in
disease duration have not been elucidated, therefore sci-
entific and clinical investigations in ALS field need an
accurate stratification of patient cohort, according to
functional decline and disease stage. This goal can be
achieved by the discover and definition of molecular
biomarkers that can help to perform an earlier and more
Fig. 2 ALS-FR score decline and patient survival during the whole study. a Exponential regression model for the ALS-FRS score during the study.
Inset: K value decline parameters of fast progressive patients were significantly higher than slow progressive patients (Mann–Whitney test
***p= 0,0002). Lifelong duration b was significantly different in slow and fast progressive patients (Log-rank Mantel–Cox test p= 0.0256) N= 11
(slow), N= 6 (fast).
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accurate diagnosis with the opportunity to start an earlier
treatment able to modify the disease course, to efficiently
enroll patients in clinical trials, and to monitor the disease
progression and identify patients who will respond better
to a specific therapeutic approach.
Over the last two decades, intensive work has been
carried out to find consistent biomarkers for ALS but,
unfortunately, none of these biomarkers has been cur-
rently translated into a practical diagnostic tool24.
In our study, we examined the absolute levels of serum
circulating miRNAs in ALS patients divided in four
groups—mild, moderate, severe and terminal stages—
according to the ALS-FRS, a parameter that define the
clinical score of the pathology.
Fig. 3 MiRNAs expression level at different stages of the disease. MiRNAs absolute RT quantification indicted that a miR-206, b miR-133a, c miR-
199a-5p, d miR-423-3p and e miR-151a-5p are differentially modulated in ALS patients at mild (I) moderate (II), severe (III), and terminal (IV) stages
compared to control individuals. Graphs indicate mean ± SEM; a N= 15 (CNT), 6 (I), 18 (II), 21 (III), 9 (IV); b N= 13 (CNT), 10 (I), 15 (II), 20 (III), 8 (IV)
c N= 18 (CNT), 7 (I), 15 (II), 15 (III), 9 (IV); d N= 15 (CNT), 7 (I), 16 (II), 16 (III), 9 (IV); e N= 16 (CNT), 7 (I), 16 (II), 16 (III), 8 (IV); Mann–Whitney test: control
vs stages *p < 0.05 **p < 0.01; Mann–Whitney test between stages #p < 0.05 ##p < 0.01.
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We initially focused our analysis on miRNAs that
resulted differentially modulated in ALS serum subjected
to NGS analysis. Three down-regulated miRNAs were
identified and validated by qPCR (miR-151a-5p, miR-
199a-5p, miR-423–3p) and where analyzed in detail. Few
miRNAs, previously identified from other research groups
up-regulated in ALS patients (e.g. miR-338–3p, miR-206
and miR-13325–28), were not detected by the analysis of
the sequencing data probably because in terms of absolute
quantities they are less expressed and therefore more
difficult to be detected through NGS. Among them, we
decided to analyze the expression of two important
myomiR such as miR-206 and miR-133a. Although their
de-regulation in ALS patients was already known25,26, no
one had previously correlated their expression with dif-
ferent stages and progression of the pathology. Moreover,
the copy number analyses confirmed that miR-206 and
miR-133a are less represented if compared to the other
miRNAs identified in sera, confirming the higher sensi-
tivity of the single qPCR assays in comparison to NGS.
Fig. 4 MiRNA expression levels in slow and fast disease progressing patients. Linear regression analysis of amiR-206, cmiR-133a, emiR-151a-5p
copies number in fast (red line) and slow (blue line) progressing patients. Roc curve analysis of b miR-206 d miR-133a, fmiR-151a-5p copies number in
fast and slow progressing patients at time of enrollment. N= 11 (slow), N= 6 (fast).
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Therefore, while the other identified miRs (miR-199a-5p
and miR-423–3p) could be useful for diagnosis (they are
highly expressed and consequently easily detectable),
miR-206 and miR-133a seem to have, together with miR-
151a-5p, a good prognostic value. We observed that low
levels of miR-199a-5p and miR-423-3p are hallmarks of
early phases of ALS pathology, while the levels of miR-
206, miR-133a, and miR-155a-5p can distinguish ALS
patients from control individuals in the mild, moderate
and severe phases. Since ALS patients exhibit different
velocity of disease progression, through a mathematical
model that account for individuals functional decline, we
were able to categorize patients of our study in fast and
slow progressing individuals and we analyzed miRNAs
levels during disease progression. By this approach, we
provided evidence that serum levels of miR-206, miR-
133a and miR-151a-5p can predict disease course and
severity. We showed that high levels of expression of
those miRNAs, in early stages of the ALS pathology,
correlated with a better prognosis and slower progression
of the disease.
Interestingly, the miRNAs analyzed, with the only
exception of miR-423, have been associated to ALS dis-
ease. Notably circulating levels of miR-151a-5p and miR-
199a-5p have been correlated with clinical variation of
ALS parameters29 and the modulation of muscle-specific
miRNAs such as miR-206 and mir-133a have been deeply
analyzed in muscle biopsies of ALS patients, confirming
their crucial role in the maintenance of muscle trophism
and neuromuscular junction plasticity26,30,31. Indeed,
Bruneteau et al.32. elucidated the direct correlation
between muscle reinnervation mediated by miR-206 and
ALS disease progression, suggesting that miR-206
expression might attenuate ALS progression, promoting
the regeneration of neuromuscular junction.
Mir-199a has been described dyseregulated during
microglial hyper-activation and persistent neuroin-
flammation, two abnormal conditions that support
pathogenensis of ALS. In addition miR-151a-5p is
thought to participate in the maintenance of cell viability
in response to oxidative stress, its expression levels
increased in the spinal cord of ALS patients, and it has
been used as a non-muscle therapeutic target in ALS
SOD1G93A mouse models13,29. Interestingly, we observed
the up-regulation of miR-151a-5p in the early phases of
the disease and its significant down-modulation in the
latest one, suggesting its involvement in the initial cell
attempts to counteract disease onset and progression.
The novelty of our study stands in three main points
that are crucial for therapeutic translation of our results.
Our study is the first to perform an absolute quantifi-
cation of circulating miRNAs in ALS patients and there-
fore provides a cut off threshold to discriminate ALS slow
progressive patients form fast progressive ones. Moreover,
our work is the first to perform a longitudinal study that
evaluates miRNAs levels during the progression of the
disease of each patient, conferring prognostic significance
to serum levels of three miRNAs analyzed, namely miR-
206, miR-133a, and miR-151a-5p. With our study we
overcome the limitation related to the absence of an ALS
biomarker that can predict disease progression in relation
to pharmacological treatment. In this context, the use of
miRNAs levels to stratify patient’s cohort in different sub-
groups depending on aggressiveness and velocity of the
Fig. 5 CPK levels in slow and fast progressing patients. Linear
regression analysis of a CPK, b albumin and c alkaline phosphatase in
fast and slow progressing patients. CPK levels decrease in both group
with higher rate decline in the fast progressing patients compared to
the slow one. Albumin and Alkaline levels do not change in both
groups a N= 11 (slow), N= 5 (fast); b N= 10 (slow), N= 4 (fast);
c N= 9 (slow), N= 3 (fast).
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disease will help clinical practice to verify the efficacy of a
treatment in clinical trial. Indeed, the possibility to iden-
tify, prior to treatment administration, those patients who
will respond or not to a given therapy, will avoid unne-
cessary treatment and could allow the development of
tailored therapy for each patient.
Until now, in the ALS field, miRNAs biomarkers have
just been proposed to discriminate normal from patho-
logical conditions; our study provides new putative bio-
markers for diagnosis, stage prediction and prognosis for
ALS disease and we believe that our results will be useful
for the development of clinical assay that can serve as
companion diagnostics in drug discovery advancement.
Materials and methods
Patients
Subjects were recruited from San Camillo Hospital—
Forlanini of Rome, Policlinico Umberto I of Rome,
Azienda Ospedaliera Universitaria ‘Città della Salute e
della Scienza’ of Turin, Fondazione Policlinico Uni-
versitario A. Gemelli IRCCS of Rome. Patients’ char-
acteristics are reported in Table 1. The study was
approved by Ethical committee of Sapienza University of
Rome Prot n. 939/17 Rif. CE 4636 and by Ethical com-
mittee of Azienda sanitaria ospedaliera “San Giovanni
Battista” of Turin Prot n. 46 (18/02/2005). The whole
study was performed in accordance with the Declaration
of Helsinki, and all the patients provided written informed
consent before the inclusion in the study.
Blood samples were collected into BD Vacutainer® SST
II Advance for serum analysis, after sedimentation (1 h
RT), serum was isolated by centrifugation (1500 rcf/min
for 10min, RT) and stored at −80 °C until use.
Small RNA sequencing
Prior to RNA extraction, 1 fmole of two Mimic RNA
Spike-in (cel-miR-2 UAUCACAGCCAGCUUUGAU
GUGC and cel-lin-4 UCCCUGAGACCUCAAGUGUGA
from Caenorhabditis elegans) was added each 200 µl of
serum. Small RNAs were extracted by miRNeasy (Qia-
gen), following the manufacturer specifications for liquid
samples. Small RNA libraries were generated from total
RNA using TruSeq Small RNA Library Preparation Kit.
Sequencing was performed on an Illumina HiSeq 2500
Sequencing system at the Institute of Applied Genomics
(IGA; Udine, Italy). An average of about 9 million 50
nucleotide long single-end reads were produced for each
sample. Read numbers and mapping statistics are repor-
ted in Supplementary Table S1.
Trimmomatic software33 was used to remove adapter
sequences, setting the simple clip threshold to 8. Reads
whose length after trimming was less than 18 nucleotides
were discarded. Bowtie34 with parameters -v 0 --best
--norc -m 1 was then used to align remaining reads to
microRNA spike-in sequences. Reads mapping to both
exogenous miRNAs were counted using a custom Python
script. Since very few reads mapped on cel-miR-2, which
was absent from most of the samples, we decided to use
only cel-lin-4 for normalization. We then used Bowtie
with --best -v 0 switches to align reads not mapping to
spike-in sequences to a sequence database composed of
canonical microRNAs and their putative isoforms; this
database, derived from mirBase 2135, is available at http://
cru.genomics.iit.it/Isomirage/. IsomiRage software36 was
used to count reads mapping on the template isoforms of
each miRNA. Read counts were supplied to DESeq2 R
package37 for differential miRNA expression analysis; size
factors were estimated using cel-lin-4 read counts. Scatter
plot of log2 fold changes versus the mean of DESeq2
normalized counts was drawn using DESeq2 plotMA
function. Heatmap of the sample-to-sample distance was
computed after applying a regularized log transformation
to count data using DESeq2 rlog function. To draw the
expression heatmap of selected miRNAs, DESeq2 nor-
malized counts were mean-centered and log2-
transformed. The Small RNA-Seq data that support the
findings of this study are openly available in the GEO
database at https://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE148097, accession number GSE148097. The
code is available under request.
RNA extraction and quantitative real-time PCR
Circulating microRNAs were extracted from 200 µl of
serum by miRCURYTM RNA Isolation Kit-Biofluids
(Exiqon Cat #EX300112). During the extraction 1 µl of
Spike-In Template Mixture (UniSp2: 2 fmoli/μl; UniSp4:
0,02 fmoli/μl; UniSp5: 0,0002 fmoli/μl) (Exiqon Cat #
203203) was added to each sample in order to allow the
absolute quantification of microRNAs.
Subsequently 4 µl of the isolated microRNAs were ret-
rotranscribed by miRCURY LNATM Universal RT
microRNA PCR, Polyadenylation, and cDNA synthesis kit
II (Exiqon Cat #EX339340) and cDNA was diluted 1:50.
Finally, 4 µl of cDNA were used for quantitative real
time PCR through ViiATM 7 Real-Time PCR System
(Applied Biosystems), using ExiLENT SYBRR Green
master mix (Exiqon Cat #203421) and Exiqon microRNAs
specific primers.
In order to obtain an absolute quantification of the
analyzed microRNAs, for each real time PCR assay a
standard curve was generated, based on Unisp2 Spike-In
template. cDNA of Unisp2 was diluted (1:10) to generate a
standard curve of defined Unisp2 copies number.
Quality analysis of total RNA extracted from plasma
In order to assess the robustness of the RNA isolation
process and the quality of the isolated microRNAs we
performed a quality control analysis.
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We extracted RNA from 200 µl of serum of a random
subgroup of 16 samples. Firstly, we checked for differ-
ences in the isolation yields performing qPCR analysis for
RNA spike-in added at known concentration of RNA
prior to RNA isolation. We observed that the purification
process was efficient for all miRNAs even those expressed
at low concentration (2–0.0002 fmoles/μl).
Secondly, we monitored cDNA synthesis by qPCR for
spike-ins miR-cel-39–3p and Unisp6, added to the pur-
ified miRNAs just before retro-transcription.
Thirdly, we performed qPCR analysis (Exiqon Cat #
203845) for the detection of 4 microRNAs to evaluate
the biological samples with regards to downstream
processing. These miRNAs are miR-103 and miR-191
which are well expressed in most tissues, and miR-451
and miR-23a which are found in plasma and serum and
serve as a haemolysis marker and as an internal control,
respectively.
This set of assays indicated a good yield of RNA isola-
tion and that the biological samples are of similar quality
with regards to miRNAs relative concentration and
haemolysis.
Absolute quantification
For all samples analyzed the mean values of the Ct
(cycle threshold) replicates of each microRNA, including
UniSp2, were calculated, and the absolute microRNA
copies number was extrapolated by comparison with the
UniSp2 standard curve. Moreover, we applied a mathe-
matical algorithm that considered the efficiency of
extraction, retro-transcription and amplification proce-
dures of UniSp2 and selected miRNAs, to overcome
experimental bias and calculate the real copy number of
circulating microRNAs in the 200 µl serum analyzed.
Statistical analysis
Statistical parameters including sample sizes (n= number
of subjects per group), the statistical test used, the statistical
significance is reported in Figure legends. Unless otherwise
indicated, p-values for simple pair-wise comparisons were
performed using a two-tailed unpaired and nonparametric
Mann–Whitney U test (*p < 0.05, **p < 0.005, ***p < 0.0005)
and graph values are reported as mean ± SEM (error bars).
To determine the minimum number of subjects for ade-
quate study power (power > 0.8) the ClinicCalc sample size
calculator was used. Statistical analysis, including ROC
curve analysis was performed using GraphPad PRISM
6 software and best cut-off was by Youden’s index
calculation.
Serological profile analysis
Blood was collected and centrifuged at 12,000 rpm for
10min. Serum was separated and stored at −80 °C.
Creatin phosphokinase (CPK), albumin and alkaline
phosphatase (ALP) determination was performed by
standard spectrophotometric analysis by using Atellica
CH CK_L, Atellica CH Alb, Atellica CH ALP_2c kits and
analyzed by the Atellica CH Analyzer system. Absorption
at 340/596 nm. 596/694 nm, 410/478 nm was measured
respectively for CPK, Albumin, ALP according to manu-
facturer instructions.
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